The whistleblowing drama behind Astellas’s suspension from the ABPI

Deborah Cohen; Shai Mulinari; Piotr  Ozieranski

doi:10.1136/bmj.l4353

The whistleblowing drama behind Astellas’s suspension from the ABPI

Deborah Cohen, Shai Mulinari, Piotr Ozieranski

Sociologi

Forskningsoutput: Tidskriftsbidrag › Letter

Sammanfattning

The Japanese drug company Astellas has had its knuckles rapped for wrongdoing four times in less than three years. Now Deborah Cohen, Shai Mulinari, and Piotr Ozieranski reveal fresh claims about the treatment of an employee who offered to help it clean up its act

Originalspråk	engelska
Artikelnummer	1453
Tidskrift	BMJ: British Medical Journal
Volym	366
DOI	https://doi.org/10.1136/bmj.l4353
Status	Published - 2019 juli 2

Ämnesklassifikation (UKÄ)

Sociologi
Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi

FN:s Globala mål

Denna forskningsoutput relaterar till följande Globala mål

Tillgång till dokument

10.1136/bmj.l4353

3 Artikel i vetenskaplig tidskrift

Failure of responsive regulation? Pharmaceutical marketing, corporate impression management and off-label promotion of enzalutamide in Europe
Mulinari, S., Davis, C. & Ozieranski, P., 2021 maj 6, I: Journal of White Collar and Corporate Crime. 2, 2, s. 69-80
Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

Öppen tillgång
Fil
146 Nedladdningar (Pure)
Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
Vilhelmsson, A., Davis, C. & Mulinari, S., 2016, I: PLoS Medicine. 13, 1, e1001945.
Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

Öppen tillgång
Fil
695 Nedladdningar (Pure)
Complaints, Complainants, and Rulings Regarding Drug Promotion in the United Kingdom and Sweden 2004–2012: A Quantitative and Qualitative Study of Pharmaceutical Industry Self-Regulation
Zetterqvist, A., Merlo, J. & Mulinari, S., 2015, I: PLoS Medicine. 12, 2, e1001785.
Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

Öppen tillgång
Fil
494 Nedladdningar (Pure)

1 Avslutade

Vad kan vi lära oss från läkemedelsindustrins nya värdeöverföringsdatabaser? En policy- och nätverksstudie av relationer mellan företag och sjukvårdspersonal- och organisationer i fyra EU-länder
Mulinari, S. (PI), Ozieranski, P. (CoI) & King, L. (CoI)
Forte, Forskningsrådet för hälsa, arbetsliv och välfärd
2017/01/01 → 2021/12/31
Projekt: Forskning

Citera det här

@article{72e40f79030c426c94eed690ef123645,

title = "The whistleblowing drama behind Astellas{\textquoteright}s suspension from the ABPI",

abstract = "The Japanese drug company Astellas has had its knuckles rapped for wrongdoing four times in less than three years. Now Deborah Cohen, Shai Mulinari, and Piotr Ozieranski reveal fresh claims about the treatment of an employee who offered to help it clean up its act",

author = "Deborah Cohen and Shai Mulinari and Piotr Ozieranski",

year = "2019",

month = jul,

day = "2",

doi = "10.1136/bmj.l4353",

language = "English",

volume = "366",

journal = "BMJ: British Medical Journal",

issn = "1756-1833",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - The whistleblowing drama behind Astellas’s suspension from the ABPI

AU - Cohen, Deborah

AU - Mulinari, Shai

AU - Ozieranski, Piotr

PY - 2019/7/2

Y1 - 2019/7/2

N2 - The Japanese drug company Astellas has had its knuckles rapped for wrongdoing four times in less than three years. Now Deborah Cohen, Shai Mulinari, and Piotr Ozieranski reveal fresh claims about the treatment of an employee who offered to help it clean up its act

AB - The Japanese drug company Astellas has had its knuckles rapped for wrongdoing four times in less than three years. Now Deborah Cohen, Shai Mulinari, and Piotr Ozieranski reveal fresh claims about the treatment of an employee who offered to help it clean up its act

U2 - 10.1136/bmj.l4353

DO - 10.1136/bmj.l4353

M3 - Letter

C2 - 31266743

SN - 1756-1833

VL - 366

JO - BMJ: British Medical Journal

JF - BMJ: British Medical Journal

M1 - 1453

ER -

The whistleblowing drama behind Astellas’s suspension from the ABPI

Sammanfattning

Ämnesklassifikation (UKÄ)

FN:s Globala mål

Tillgång till dokument

Fingeravtryck

Forskningsoutput

Failure of responsive regulation? Pharmaceutical marketing, corporate impression management and off-label promotion of enzalutamide in Europe

Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.

Complaints, Complainants, and Rulings Regarding Drug Promotion in the United Kingdom and Sweden 2004–2012: A Quantitative and Qualitative Study of Pharmaceutical Industry Self-Regulation

Projekt

Vad kan vi lära oss från läkemedelsindustrins nya värdeöverföringsdatabaser? En policy- och nätverksstudie av relationer mellan företag och sjukvårdspersonal- och organisationer i fyra EU-länder

Citera det här